Clik here to view.
Cullgen Announces Expanded Scientific Advisory Board
DELAWARE Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination),...
View ArticleClik here to view.
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for...
ROCKVILLE, Md. Genexine, a clinical stage biotechnology company developing innovative biologics, and its spin-off company in the US, NeoImmuneTech, Inc. (NIT), today announced that Hyleukin-7, their...
View ArticleClik here to view.
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase...
SEATTLE & HANGZHOU, China Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer,...
View ArticleClik here to view.
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line)...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Hervycta® (trastuzumab...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) announced today that it has launched Hervycta® (trastuzumab), a biosimilar of Roche’s Herceptin®, in India, indicated for...
View ArticleClik here to view.
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) +...
CASTRES, France Pierre Fabre today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of...
View ArticleClik here to view.
武田薬品、ALUNBRIG®（ブリガチニブ）の第3相試験が主要評価項目を達成し、ALK阻害剤未治療の進行性ALK陽性NSCLC患者でクリゾチニブと比較して...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502）は本日、グローバルランダム化第3相ALTA-1L試験（ALK in Lung Cancer Trial of AP26113 in 1st...
View ArticleClik here to view.
武田宣布3期ALUNBRIG®...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，全球随机3期ALTA-1L（ALK in Lung Cancer Trial of AP26113 in 1st...
View ArticleClik here to view.
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1...
PLEASANTON, Calif. & TOKYO Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASTRAL-1 study evaluating the...
View ArticleClik here to view.
Takeda Reports First Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +6.4% with growth in every region Underlying Revenue grew +6.4%, led by Takeda’s Growth Drivers...
View ArticleClik here to view.
2018年度第1四半期（4-6月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益は＋6.4％、すべての地域で増収 売上収益の実質的な成長は、タケダの成長ドライバー（消化器系疾患領域、オンコロジー、ニューロサイエンス、新興国事業）の＋11.8％の力強い伸長により、対前年同期＋6.4％、主力製品であるエンティビオ（＋34.1％）およびニンラーロ（＋43.3％）が大きく貢献...
View ArticleClik here to view.
CANbridge Life Sciences Appoints Chief Medical Officer
BEIJING CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that it strengthened the executive management team with the...
View ArticleClik here to view.
武田公布2018财年第一季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502)： 基础营收增长+6.4%，各个地区均有增长 基础营收增长+6.4%，武田的增长引擎（胃肠药、肿瘤药、神经科药物和新兴市场）与前一年相比展现了强劲增长，增幅达到+11.8%。主要产品Entyvio (+34.1%)和Ninlaro...
View ArticleClik here to view.
Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I...
View ArticleClik here to view.
KIST: Overcoming the Current Limitations of Cancer Immunotherapy Through...
SEOUL, South Korea Cancer immunotherapy harnessing the immune system to treat cancer is drawing a lot of attention of many medical staff and researchers because of unprecedented responses in the...
View ArticleClik here to view.
和铂医药与Glenmark Pharmaceuticals签署同类首创双特异性抗体药物战略合作与独家授权协议
中国上海，美国波士顿，印度孟买和瑞士La Chaux de Fonds (美国商业资讯)–全球化的生物制药公司和铂医药与Glenmark Pharmaceuticals S.A. 宣布签署一项独家授权协议，在大中华区开发、生产以及商业化GBR 1302。这是一种由Glenmark开发的用于治疗HER2阳性癌症的靶向HER2和CD3的双特异性抗体创新药物。...
View ArticleClik here to view.
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China...
BOSTON & SHANGHAI & MUMBAI, India & LA CHAUX DE FONDS, Switzerland Harbour BioMed and Glenmark Pharmaceuticals S.A., announced today that they have entered into an exclusive license...
View ArticleClik here to view.
Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and...
View ArticleClik here to view.
AVEO Announces Acceptance of CANbridge Investigational New Drug Application...
CAMBRIDGE, Mass. AVEO Oncology (Nasdaq: AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for...
View ArticleClik here to view.
CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in...
BEIJING CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that the China National Drug Administration (CNDA) has approved the...
View Article